기본 콘텐츠로 건너뛰기

추천 가젯

[스크리너 톱600-514] 유바이오로직스 - 콜레라 백신 원툴, 조달가는 매년 낮아진다

밸류체인 플랫폼의 저평가 스크리너를 순서대로 뜯어보는 연재, 511~520번 구간입니다. 514번 유바이오로직스(206650). 기준일 2026-08-28, 스크리너 점수 56.5점 — 저평가 컷(67.2점)에 10.7점 모자란 '적정' 판정 입니다. 경구용 콜레라 백신으로 국제기구 조달시장을 잡은 회사 유바이오로직스는 경구용 콜레라 백신 '유비콜' 시리즈를 개발·생산하는 백신 전문기업이다. 춘천에 생산기지를 두고 있고, WHO 사전적격성평가(PQ) 인증을 받은 유비콜은 유니세프(UNICEF) 등 국제기구가 주관하는 글로벌 콜레라 백신 공공조달 시장에 공급된다. 매출의 절대 축이 이 조달 물량이라는 점이 이 회사를 이해하는 출발점이다. 코스닥 상장사다. 연도 매출(억원) 영업이익(억원) 순이익(억원) 2022 555 -38 -11 2023 694 77 -139 2024 960 343 191 2025 1,492 607 413 매출은 2022년 555억원에서 2025년 1,492억원으로 3년 만에 세 배 가까이 늘었고, 2022년 영업적자였던 손익은 2024년 흑자전환 뒤 2025년 영업이익 607억원(영업이익률 40.7%)까지 확대됐다. 순이익도 2024년 191억원, 2025년 413억원으로 규모가 커졌다 — 순이익이 영업이익보다 낮은 격차는 법인세 등 통상 수준으로, 별도의 일회성 요인은 확인되지 않는다. 시가총액 3,495억원, PER 12.0배·PBR 1.99배·ROE 16.7% (TTM). 제약/바이오 피어 72개 PER 중앙값(13.67배)보다 오히려 낮다 — 이 구간에서 흔한 "피어보다 비싼" 사례는 아니다. 왜 스크리너 514위인가 원점수 56.2(순위 중하위권)는 정규분포 정규화를 거쳐 59.8점이 됐는데, 이 값부터 이미 저평가 컷(67.2)에 7.4점 못 미친다. 여기에 소속 산업(제약/바이오)의 최근 6개월 수익률이 -31.6%로 순환매 밴드 하위에 들어 -5.0점 감...

Korean Solar’s Last Card Against China’s Oversupply: The U.S. Market and a Non-China Supply Chain

When you revisit Korea’s solar value chain, the answer is colder than you might expect. The chain runs long—from polysilicon to cells and modules, inverters, and EPC—but in today’s market, China effectively holds the pricing power. Cells and modules have already seen a wide cost gap open up, and as a result, pure-play domestic manufacturing has entered a phase where production cuts and losses are hard to avoid. This is no longer a question of whether the technology exists; it has become a question of who is plugged into which markets and policy regimes.

The survival condition for Korea’s solar manufacturing industry right now is not going head-to-head with China, but positioning itself on the policy detour of the U.S. and non-China supply chains. That’s why, when looking at this value chain, the first question is not simply which companies make good products, but which ones are actually benefiting from the U.S. IRA and AMPC, or can command a non-China supply chain premium. There is clearly still hope. But we also have to face the uncomfortable reality that this hope is not called technological innovation—it is called policy.

Polysilicon, Cells, Modules — From Raw Materials to Panels (4 companies)

In the first stretch of the value chain, from raw materials to panels, the two names that stand out most clearly are OCI Holdings and Hanwha Solutions. OCI Holdings is the only domestic player in polysilicon, the core raw material for solar power, and with its production base in Malaysia, it carries the symbolism of a non-China supply chain. In a market flooded with Chinese products, that single point of differentiation matters more than it seems. It may lose on price alone, but in an era of supply-chain realignment, it has every reason to be called back into focus.

In the polysilicon-cell-module segment, there are really only two pillars Korean companies can lean on: OCI Holdings’ non-China polysilicon and Hanwha Solutions Qcells’ No. 1 position in the U.S. residential market. Hanwha Solutions’ Qcells has ranked No. 1 in the U.S. residential market for eight straight years, with a market share of 38.5%. Add in the benefits of the IRA, and even as domestic manufacturing collapses, a path to survival in the U.S. still emerges. HD Hyundai Energy Solutions, an affiliate of HD Hyundai, continues to operate its cell and module business, with modules accounting for about 73% of sales. Shinsung E&G runs a dual-track structure spanning solar cells and modules as well as semiconductor and display cleanrooms. But to be blunt, in this segment the direction of policy matters more than production capacity in determining winners and losers. If the U.S. opens the door, the pressure eases; if it shuts it, it becomes another endurance game.

CompanyCore focus
OCI HoldingsPolysilicon (solar raw material) — the only domestic player; produced in Malaysia (non-China supply chain)
Hanwha SolutionsSolar cells and modules (Qcells) — No. 1 in U.S. residential for 8 consecutive years (~38.5%, IRA beneficiary)
HD Hyundai Energy SolutionsSolar cells and modules (modules account for ~73% of sales) — HD Hyundai affiliate
Shinsung E&GTwo main businesses: solar cells/modules + semiconductor/display cleanrooms

Inverters, EPC, and Power Generation — Turning Panels into Electricity, and into Power Plants (4 companies)

The next stage—where panels are turned into actual electricity and assembled into power plants—is inverters, EPC, and O&M. When margins collapse in manufacturing alone, system and project capabilities offer a less commoditized form of competition. That does not mean this segment is a safe haven. If the wave of low-cost Chinese products moves down from the upper end of the value chain, this side will eventually face pricing pressure too. Even so, this is exactly where Korean companies still have some room to soften the damage from manufacturing.

The inverter, EPC, and power generation segment is the last buffer zone where Korean companies can hold their ground with system design and project execution capabilities, even amid the onslaught of low-cost Chinese panels. Willings spans solar inverters, ESS power conversion systems (PCS), and EPC, and has a track record as the world’s first company to develop a 2MW multi-string inverter. Dasstech is unlisted, but is considered one of Korea’s key solar inverter manufacturers. S-Energy’s strength lies in its vertical capabilities, combining solar module manufacturing with power-generation EPC and O&M through S-Power, while SDN operates across solar modules, power-generation EPC, and maintenance, alongside an outboard engine business. In the end, companies in this segment are not just trying to sell a single panel—they are looking for profits in how to design and operate an entire power plant. It is hard to see another path.

CompanyCore focus
WillingsSolar inverters, ESS power conversion (PCS), EPC — world’s first 2MW multi-string inverter
DasstechA major domestic solar inverter manufacturer (unlisted)
S-EnergySolar module manufacturing + vertically integrated power-generation EPC and O&M capabilities (S-Power)
SDNSolar modules, power-generation EPC, maintenance (+ also operates an outboard engine business)

What to Watch Going Forward

When talking about the road ahead, excessive optimism is dangerous. Dressing up the future of Korea’s domestic solar manufacturing in technological optimism is far removed from reality. China’s oversupply is already too deep, and the cost gap in cells and modules is not something that can be closed easily. That leaves a clear path: securing a place in the China-excluding supply chain realignment being pushed by the U.S. and Europe. Within that framework, OCI Holdings’ Malaysian polysilicon and Hanwha Solutions Qcells’ U.S. footprint look like the most realistic cards on the table.

What will determine the future of Korea’s solar manufacturing industry is not technological superiority, but whether policies such as the U.S. IRA remain in place. That is exactly why the Trump-driven risk of IRA rollback is a variable that could shake the very premise of the industry outlook. If U.S. policy holds, Korean companies may be given more time to survive. If the IRA wavers, however, both the premium on non-China supply chains and expectations for profitability in the U.S. are likely to weaken as well. There is still hope. But that hope does not stand on self-sustaining market competitiveness alone. China’s oversupply will continue, and policy can change at any time. The most honest way to look at Korean solar right now is to start by not looking away from this uncomfortable truth.

※ This article organizes company names, core businesses, and market positions based on publicly available materials verified online, and some assessments reflect the author’s own views. It is not intended as a direct basis for investment decisions.

Written: July 2026. Ealexandro

댓글

가장 많이 본 글